RAPT Therapeutics
RAPT
RAPT was delisted on the 2nd of March, 2026.
108 hedge funds and large institutions have $895M invested in RAPT Therapeutics in 2023 Q4 according to their latest regulatory filings, with 21 funds opening new positions, 38 increasing their positions, 36 reducing their positions, and 8 closing their positions.
163% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 8
104% more call options, than puts
Call options by funds: $15.3M | Put options by funds: $7.54M
55% more capital invested
Capital invested by funds: $578M → $895M (+$318M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
13% more funds holding
Funds holding: 96 → 108 (+12)
6% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 36
0.44% more ownership
Funds ownership: 12.65% → 13.09% (+0.44%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$20.6M |
| 2 |
SC
Samlyn Capital
New York
|
+$11M |
| 3 |
TCM
TimesSquare Capital Management
New York
|
+$7.8M |
| 4 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$4.55M |
| 5 |
OCA
Octagon Capital Advisors
New York
|
+$4.52M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$14.9M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$10.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$10.1M |
| 4 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$5.54M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$4.99M |
RAPT Hedge Fund Activity: Q4 2023 in Review
108 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in RAPT Therapeutics (RAPT) for Q4 2023, worth a combined $895M — up 55% from $578M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new RAPT positions and 8 closed out — a net gain of 13 holders — while 38 added to existing stakes and 36 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $20.6M. The largest seller was OrbiMed, cutting an estimated $14.9M.
- 108 institutional investors held RAPT Therapeutics (RAPT) as of Q4 2023, up from 96 in Q3 2023.
- Funds reported $895M of RAPT Therapeutics stock for Q4 2023, up 55% quarter-over-quarter.
- 21 funds opened new RAPT Therapeutics positions in Q4 2023 and 8 closed out, a net change of +13 holders.
- The largest RAPT Therapeutics buyer in Q4 2023 was Morgan Stanley, an estimated $20.6M added.
- The largest RAPT Therapeutics seller in Q4 2023 was OrbiMed, an estimated $14.9M sold.
Based on aggregated 13F filings for Q4 2023.